In addition to the observation that all melanomas of mice from the group treated with the combination had reduced phospho-ERK1/2 levels, there was a significant increase in JUN protein levels after the combination treatment with trametinib and DSF in all three BRAF WT PDX models even after the single application of the drugs. This evidence concerns the gene MAPK3 and melanoma.